Melanoma and other skin tumours

1036O 

Relatlimab (RELA) + Nivolumab (NIVO) Vs. NIVO in Previously Untreated Metastatic or Unresectable Melanoma: Additional Efficacy in RELATIVITY-047

F.S. Hodi, et al.

Conclusions

RELA + NIVO FDC had demonstrated prolonged PFS in ITT and subgroups of pts with previously untreated metastatic or unresectable melanoma. Pts on RELA + NIVO FDC had enduring benefit beyond initial treatment and prolonged benefit beyond first progression, including longer time to initiation of subsequent treatment.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1036O.html.pdf

 

1040O 

Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

J.S. Weber, et al.

Conclusions

Flipped dose IPI/NIVO with TOCI has promising anti-tumor activity with a favorable toxicity profile. Incidence of grade 3/4 irAEs was 25%. High baseline TNF-a was associated with grade 3/4 irAEs, and elevated week 7 IL-6/IL-8/C5a were associated with progression. Further correlative studies will be presented.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1040O.html.pdf

 

1037O 

MASTERKEY-265: A phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

Ribas

Conclusions

T + P did not significantly improve PFS or OS vs Pbo + P. There was a 5.8 mo numeric difference in PFS between arms. Safety results of T + P were acceptable and consistent with the known safety profiles of each agent.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/1037O.html.pdf